Polygeline Injection Sales

Polygeline Injection Sales Market Outlook

The global Polygeline Injection market is projected to reach approximately USD 2.5 billion by 2035, with a compound annual growth rate (CAGR) of about 6.5% during the forecast period from 2025 to 2035. This growth is largely driven by the increasing prevalence of surgical procedures and trauma cases that require effective volume replacement solutions. Additionally, the rising geriatric population, which is more susceptible to hypovolemia and related conditions, significantly contributes to the growing demand for Polygeline injections. The expansion of healthcare infrastructure in emerging economies, coupled with advancements in medical technologies, is expected to further propel the market. Furthermore, increased awareness regarding the benefits of Polygeline as a safe and effective fluid replacement therapy in various medical conditions is likely to boost market penetration.

Growth Factor of the Market

The growth of the Polygeline Injection market can be attributed to several key factors. The first is the escalating number of surgeries performed worldwide, which creates a higher demand for blood volume expanders like Polygeline. Hospitals and surgical centers are increasingly relying on this product to manage fluid balance during surgical procedures, thereby enhancing patient outcomes. Second, the rising incidence of trauma cases, including those resulting from accidents or natural disasters, has led to a greater need for rapid volume expansion, making Polygeline an essential component in emergency care settings. Third, the growing focus on patient safety and the minimization of complications during surgery has positioned Polygeline as a preferred choice due to its favorable safety profile compared to traditional alternatives. Additionally, the rise in outpatient surgical procedures has also contributed to the demand, as they require efficient fluid management systems to ensure patient recovery. Lastly, ongoing research and development initiatives aiming to enhance the formulations and delivery mechanisms of Polygeline will likely contribute to market growth.

Key Highlights of the Market

• Projected global market size of USD 2.5 billion by 2035 with a 6.5% CAGR.
• Increased demand driven by surgical procedures and trauma management.
• Growth in healthcare infrastructure in emerging markets.
• Enhancements in Polygeline formulations expected to drive market innovation.
• Rising awareness about patient safety fostering greater adoption of Polygeline injections.

By Product Type

Polygeline 3.5%:

The Polygeline 3.5% product type is one of the most commonly used formulations in clinical practice. It is particularly effective in patients with mild to moderate hypovolemia. This concentration is often preferred for its balanced efficacy and safety profile, making it suitable for various clinical scenarios. The demand for Polygeline 3.5% is bolstered by its application in both surgical and non-surgical settings, encompassing elective procedures and trauma management. The versatility of this formulation has also been noted in outpatient settings, where rapid recovery of fluid balance is essential for discharge. As a result, Polygeline 3.5% is expected to maintain a significant share of the overall market as healthcare providers continue to prioritize effective fluid management strategies.

Polygeline 4%:

Polygeline 4% is another crucial segment within the market, commonly utilized for more severe cases of hypovolemia. Its slightly higher concentration allows for more effective fluid expansion, helping to stabilize patients with greater fluid deficits. This formulation is particularly integral during high-risk surgical procedures where significant blood loss may occur. The growing number of complex surgeries, such as cardiac and orthopedic operations, is expected to drive the demand for Polygeline 4%. As clinicians focus on improving patient outcomes and minimizing transfusion rates, Polygeline 4% stands out as a reliable option for volume replacement therapy.

Polygeline 5%:

Polygeline 5% has emerged as a critical player in advanced fluid management, particularly in trauma care and critical care settings. The higher concentration of this formulation significantly enhances its effectiveness in expanding blood volume quickly, which is vital in emergency situations. This product is often used in conjunction with other resuscitation fluids to optimize patient management during critical interventions. With a growing emphasis on improving trauma care protocols globally, the demand for Polygeline 5% is forecasted to rise substantially, especially in regions with high trauma incidence rates.

Polygeline 6%:

The Polygeline 6% formulation is tailored for specific clinical scenarios where rapid and substantial fluid resuscitation is required. This concentration is particularly beneficial for patients undergoing extensive surgeries or those in critical condition. Its increased effectiveness in enhancing blood volume makes it a preferred choice among healthcare professionals during emergencies. The growing trend of personalized medicine and tailored treatment approaches is expected to enhance the adoption of Polygeline 6%, as clinicians seek optimal outcomes for their patients. This segment is poised for growth, especially in well-equipped healthcare institutions that prioritize advanced fluid management technologies.

Polygeline 7%:

Polygeline 7% is the highest concentration available in the market and is utilized in specialized settings where extreme volume expansion is necessary. This formulation is commonly applied in major trauma situations or in patients with severe hypovolemic shock. The use of Polygeline 7% aids in quickly restoring hemodynamic stability, which is crucial for survival in critical care scenarios. As hospitals and emergency departments enhance their capabilities to deal with life-threatening conditions, the demand for Polygeline 7% is expected to increase significantly, leading to its growing market share. Furthermore, continuous clinical studies and trials are likely to validate its efficacy, allowing for broader acceptance across various healthcare settings.

By Application

Hypovolemia Treatment:

The treatment of hypovolemia is one of the primary applications of Polygeline injections. Hypovolemia, characterized by a deficit of blood volume in the body, can result from a variety of causes including hemorrhage, dehydration, and surgical fluid loss. Polygeline serves as an effective volume expander, helping to restore hemodynamic stability and improve oxygen delivery to tissues. As the prevalence of conditions leading to hypovolemia increases, particularly among the aging population and those undergoing complex surgical procedures, the demand for Polygeline injections specifically for this application is expected to grow significantly. Healthcare professionals increasingly recognize the importance of rapid volume restoration, further solidifying Polygeline’s role in critical care settings.

Blood Volume Expansion:

Another vital application of Polygeline injections is in blood volume expansion. This application is particularly critical in surgical and trauma settings where rapid restoration of blood volume is required to prevent shock and ensure optimal organ perfusion. Polygeline's unique properties make it highly effective in expanding plasma volume quickly, making it a go-to solution for anesthesiologists and critical care physicians. The rising incidence of surgeries and traumatic injuries globally contributes to the increasing need for effective blood volume expanders, and Polygeline stands out due to its safety profile and efficacy. This segment is expected to see robust growth, driven by advancements in surgical techniques and increased patient throughput in healthcare facilities.

Burns & Trauma Management:

Polygeline injections are also extensively utilized in burns and trauma management, where prompt and effective fluid resuscitation is essential for patient survival. In cases of severe burns, fluid loss can be significant, requiring immediate intervention to restore volume and maintain circulatory stability. Polygeline provides a rapid and effective solution for managing these critical situations. The rising incidence of accidents and burns emphasizes the need for effective management protocols, and Polygeline has proven to be a reliable option in emergency care. As countries invest in improving their emergency response systems and trauma care, the relevance of Polygeline in this application will continue to expand.

Surgical Procedures:

In surgical procedures, Polygeline is primarily used as a fluid replacement therapy to ensure optimal hemodynamic stability. The nature of many surgical interventions often leads to fluid shifts and blood loss, which necessitate the use of effective volume expanders like Polygeline. Surgeons and anesthesiologists increasingly favor Polygeline due to its rapid action and lower risk of complications compared to traditional crystalloids and colloids. The growing number of surgical procedures, alongside advancements in minimally invasive techniques, underscores the importance of effective fluid management, further propelling the demand for Polygeline during surgeries. This application segment is expected to thrive as surgical volumes continue to rise globally.

Others:

Beyond the primary applications, Polygeline injections find utility in various other medical scenarios. These may include elective surgeries, outpatient procedures, and specific patient management protocols in critical care settings. The versatility of Polygeline allows it to be integrated into diverse treatment plans, catering to unique patient needs. Additionally, ongoing research into new applications and indications for Polygeline could further broaden its relevance in the healthcare market. The "Others" application segment represents a growing area of interest that may see increased attention as healthcare providers seek innovative solutions for diverse clinical challenges.

By Distribution Channel

Hospitals:

Hospitals serve as the primary distribution channel for Polygeline injections due to their critical role in managing a wide array of medical conditions, particularly surgical and emergency cases. The demand for Polygeline in hospital settings is driven by a high volume of surgical procedures and trauma care, where rapid and effective fluid resuscitation is paramount. Most hospitals have established protocols for fluid management, often including Polygeline as a key component. As healthcare systems evolve and adapt to increasing patient loads, the reliance on effective volume expanders like Polygeline in hospitals is expected to grow, solidifying their position as the leading distribution channel in the market.

Clinics:

Clinics also play a significant role in the distribution of Polygeline injections, particularly in outpatient settings where minor surgical procedures and trauma management occur. Many clinics are equipped to handle situations requiring fluid resuscitation, and Polygeline offers a reliable and effective option for maintaining patient stability. The increasing shift towards outpatient care models, driven by advancements in minimally invasive techniques, is likely to enhance the uptake of Polygeline in these settings. Clinics’ focus on improving patient care and outcomes aligns with the utilization of effective products like Polygeline, driving its demand in this distribution channel.

Ambulatory Surgical Centers:

Ambulatory Surgical Centers (ASCs) are emerging as a vital distribution channel for Polygeline injections, particularly as the trend toward outpatient surgeries continues to grow. These centers specialize in providing surgical procedures that do not require hospitalization, where effective fluid management is essential for patient recovery. Polygeline's properties make it an ideal choice in ASCs, as they often prioritize products that enhance patient outcomes while minimizing recovery time. The increasing volume of procedures performed at ASCs highlights the importance of Polygeline in this channel, driving its demand as healthcare shifts towards more efficient care delivery models.

Online Pharmacies:

The rise of online pharmacies as a distribution channel for Polygeline injections reflects the growing trend of e-commerce in the healthcare sector. While Polygeline is predominantly used in clinical settings, the availability of such products through online platforms can facilitate ease of access for healthcare providers. This distribution channel is particularly beneficial for smaller clinics and independent practitioners who may require prompt access to essential medications. The convenience of ordering online, coupled with the increasing comfort of healthcare providers with digital platforms, is likely to drive demand for Polygeline injections through this channel, although regulatory considerations will play a significant role in shaping this market segment.

Others:

The "Others" distribution channel encompasses various avenues through which Polygeline injections may be acquired, including specialty pharmacies, medical supply companies, and healthcare distributors. These channels often cater to specific needs and may provide personalized service to healthcare facilities looking for tailored supply solutions. As hospitals and clinics seek to optimize their procurement processes, these alternative distribution avenues can play a complementary role in ensuring a continuous supply of Polygeline injections. The growth of this segment will largely depend on the evolving healthcare landscape and the demand for efficient supply chain solutions.

By Ingredient Type

Polygeline:

Polygeline itself is the primary ingredient in these injections, known for its effectiveness as a volume expander. As a gelatin-based colloid, Polygeline works by increasing plasma volume, making it particularly valuable during surgical procedures and in trauma care. Its unique molecular structure allows for rapid expansion of blood volume, aiding in the stabilization of patients experiencing fluid deficits. The growing recognition of Polygeline's safety profile and efficacy among healthcare professionals has contributed to its widespread adoption. As the market evolves, ongoing research into Polygeline formulations is likely to enhance its applications and effectiveness in various medical scenarios.

Electrolytes:

Electrolytes are often incorporated into Polygeline formulations to ensure that patients receive balanced fluid replacement therapy. The inclusion of electrolytes is vital for maintaining homeostasis and proper cell function, especially in patients experiencing significant fluid loss. This ingredient type enhances the overall effectiveness of Polygeline, making it suitable for a wider range of medical applications. As healthcare providers increasingly prioritize comprehensive patient management, the demand for Polygeline injections that include electrolytes is expected to grow, further driving the market. The collaborative role of Polygeline and electrolytes highlights the importance of integrating multiple components to achieve optimal patient outcomes.

By Region

The North American region is anticipated to dominate the Polygeline Injection market, contributing approximately 40% of the total revenue by 2035. This growth is primarily driven by the advanced healthcare infrastructure, high surgical volumes, and increasing awareness among healthcare providers regarding effective fluid management solutions. The United States, in particular, is witnessing an upsurge in the number of surgeries performed annually, which directly correlates to the demand for Polygeline injections. Furthermore, the presence of key market players and ongoing research activities in this region are expected to facilitate innovation and enhance market growth. The CAGR for the North American market is projected to be around 7% during the forecast period, reflecting robust growth driven by a focus on improving patient outcomes.

Europe is another vital market for Polygeline injections, accounting for approximately 30% of the global market share. The region benefits from a well-established healthcare system and a growing geriatric population that increasingly requires surgical interventions. Besides, rising incidences of trauma and emergency cases necessitate effective fluid management solutions, positioning Polygeline as a crucial therapeutic option. Countries such as Germany, France, and the UK are leading in terms of market contribution, with collaborative efforts among healthcare stakeholders aimed at enhancing patient care in surgical settings. The European market is expected to witness a CAGR of around 5.5%, driven by advancements in surgical techniques and increased awareness of fluid management protocols.

Opportunities

The Polygeline Injection market presents numerous opportunities, particularly within developing regions where healthcare infrastructure is expanding. The increasing number of hospital setups and surgical centers in Asia Pacific, Latin America, and the Middle East & Africa presents a lucrative opportunity for market players. As these regions experience rapid urbanization and an escalating demand for healthcare services, the need for effective volume expanders like Polygeline is poised to rise significantly. Additionally, initiatives aimed at improving healthcare access and quality further enhance the market landscape, allowing for greater penetration of Polygeline products. Manufacturers that strategically align themselves with the growth of healthcare facilities in these regions are likely to capture a substantial market share and establish themselves as leaders in fluid management solutions.

Furthermore, ongoing advancements in medical research and technology present significant opportunities for innovation within the Polygeline Injection market. Research into new formulations, delivery mechanisms, and combination therapies could expand the therapeutic applications of Polygeline. For instance, exploring its potential use in managing chronic conditions or as part of enhanced recovery protocols following surgeries could create new market avenues. Additionally, partnerships between pharmaceutical companies and healthcare institutions for clinical trials and product development could lead to more tailored solutions, driving demand and broadening the scope of Polygeline injections in modern medical practice. These opportunities signal a promising future for market stakeholders willing to invest in research and development.

Threats

Despite the promising outlook for the Polygeline Injection market, there are inherent threats that stakeholders must navigate. One of the most significant threats is the increasing competition from alternative products and therapies, including other volume expanders and different classes of fluid replacement solutions. New entrants in the market often introduce innovative alternatives that target the same patient demographics, creating price pressure and potentially eroding market share for established products like Polygeline. Additionally, the development of safer alternatives, particularly those that do not carry the risk of allergic reactions or other side effects, could pose a challenge to Polygeline's market position. As the healthcare landscape continues to evolve, market players must remain vigilant and adaptive to maintain their competitive edge.

Moreover, regulatory hurdles and stringent compliance requirements can also act as restraining factors for the Polygeline Injection market. The approval process for new formulations and the need for extensive clinical trials to establish safety and efficacy can delay product launches and increase costs for manufacturers. Furthermore, adverse publicity or incidents related to the use of Polygeline injections could lead to heightened scrutiny from regulators and health authorities, ultimately impacting market growth. Companies must be proactive in ensuring compliance with regulations and maintaining high safety standards to mitigate these threats and retain consumer trust.

Competitor Outlook

• Baxter International Inc.
• Fresenius Kabi AG
• Grifols S.A.
• Otsuka Pharmaceutical Co., Ltd.
• Octapharma AG
• Hyaluronic Acid Laboratory Inc.
• Merck KGaA
• Johnson & Johnson
• TEVA Pharmaceutical Industries Ltd.
• Amgen Inc.
• Shire Plc
• Roche Holding AG
• Pfizer Inc.
• Sanofi S.A.
• AbbVie Inc.

The competitive landscape of the Polygeline Injection market is characterized by a mix of well-established pharmaceutical companies and emerging players striving to capture market share. Major companies such as Baxter International Inc., Fresenius Kabi AG, and Grifols S.A. dominate the space, leveraging their extensive distribution networks and brand recognition. These companies continuously invest in research and development efforts aimed at enhancing product formulations and expanding their portfolios to include innovative therapies. Additionally, collaborations and partnerships with healthcare providers and institutions are key strategies employed by these major players to improve their offerings and ensure widespread adoption of their products.

Furthermore, the influx of new entrants into the Polygeline market signifies the growing recognition of the potential for profitability within this segment. As the market expands, smaller companies are attempting to carve out niches by developing specialized formulations or targeting specific demographics. These entrants often leverage agility and innovative strategies to differentiate themselves, which can lead to heightened competition in the future. Mergers and acquisitions among both established and emerging players are also anticipated, as companies seek to enhance their capabilities and broaden their reach in the market.

Key players in the Polygeline Injection market are also focused on addressing the challenges posed by regulatory changes and market dynamics. Companies such as Otsuka Pharmaceutical Co., Ltd. and Octapharma AG emphasize compliance with stringent regulations while prioritizing safety and efficacy in their product development. Additionally, these organizations are keen on fostering relationships with regulatory bodies to facilitate smoother approval processes for new products. Overall, the competitive landscape is marked by a blend of innovation, strategic partnerships, and a strong focus on patient safety, ultimately driving the growth of the Polygeline market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Shire Plc
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Merck KGaA
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AbbVie Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Grifols S.A.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Octapharma AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Roche Holding AG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Fresenius Kabi AG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Johnson & Johnson
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Baxter International Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hyaluronic Acid Laboratory Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Otsuka Pharmaceutical Co., Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 TEVA Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Polygeline Injection Sales Market, By Application
    • 6.1.1 Hypovolemia Treatment
    • 6.1.2 Blood Volume Expansion
    • 6.1.3 Burns & Trauma Management
    • 6.1.4 Surgical Procedures
    • 6.1.5 Others
  • 6.2 Polygeline Injection Sales Market, By Product Type
    • 6.2.1 Polygeline 3.5%
    • 6.2.2 Polygeline 4%
    • 6.2.3 Polygeline 5%
    • 6.2.4 Polygeline 6%
    • 6.2.5 Polygeline 7%
  • 6.3 Polygeline Injection Sales Market, By Ingredient Type
    • 6.3.1 Polygeline
    • 6.3.2 Electrolytes
  • 6.4 Polygeline Injection Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Polygeline Injection Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Polygeline Injection Sales market is categorized based on

By Product Type

• Polygeline 3.5%
• Polygeline 4%
• Polygeline 5%
• Polygeline 6%
• Polygeline 7%

By Application

• Hypovolemia Treatment
• Blood Volume Expansion
• Burns & Trauma Management
• Surgical Procedures
• Others

By Distribution Channel

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Online Pharmacies
• Others

By Ingredient Type

• Polygeline
• Electrolytes

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Baxter International Inc.
• Fresenius Kabi AG
• Grifols S.A.
• Otsuka Pharmaceutical Co., Ltd.
• Octapharma AG
• Hyaluronic Acid Laboratory Inc.
• Merck KGaA
• Johnson & Johnson
• TEVA Pharmaceutical Industries Ltd.
• Amgen Inc.
• Shire Plc
• Roche Holding AG
• Pfizer Inc.
• Sanofi S.A.
• AbbVie Inc.